论文部分内容阅读
目的探讨聚乙二醇α-2a干扰素(PEGINFα-2a)治疗HBeAg阳性慢性乙型肝炎的疗效和安全性。方法按随机对照原则选择80例HBVDNA、HBeAg阳性的慢性乙型肝炎患者,按1∶1随机分配进入PEGINFα-2a组和IFNα-2a组。结果治疗6个月时,PEGINFα-2a组HBeAg血清转换率(45.7%)高于IFNα-2a组(35.1%),但P>0.05。停药6个月后,持续的HBeAg血清转换率分别为48.6%和37.8%,P>0.05。停药6个月后,持续的HBVDNA阴转率分别为62.9%和45.9%,P>0.05。治疗后,两组的丙氨酸转氨酶(ALT)复常率差异无显著性,为62.9%和45.9%,停药后6个月,两组的联合应答率分别为57.1%和40.5%。PEGINFα-2a组有3例患者HBsAg阴转,而IFNα-2a组仅有1例患者HBsAg阴转。两组有相似的不良反应,不良反应间差异无统计学意义,两组治疗过程中均未发生重要的不良事件。结论PEGINFα-2a治疗HBeAg阳性的慢性乙型肝炎疗效优于普通干扰素IFN-2a,耐受性和安全性好。
Objective To investigate the efficacy and safety of PEGINFα-2a in the treatment of HBeAg-positive chronic hepatitis B patients. Methods Eighty patients with HBVDNA and HBeAg positive chronic hepatitis B were randomly divided into PEGINFα-2a group and IFNα-2a group according to randomized control. Results At 6 months, the HBeAg seroconversion rate (45.7%) in PEGINFα-2a group was higher than that in IFNα-2a group (35.1%), but P> 0.05. After six months of discontinuation, the sustained HBeAg seroconversion rates were 48.6% and 37.8%, respectively, P> 0.05. After six months of discontinuation, the sustained negative rates of HBVDNA were 62.9% and 45.9%, respectively, P> 0.05. After treatment, there was no significant difference in alanine aminotransferase (ALT) recovery between the two groups (62.9% and 45.9%, respectively). After 6 months of discontinuation, the combined response rates of the two groups were 57.1% and 40.5%, respectively. Three patients in the PEGINFα-2a group had HBsAg negative, whereas only one patient in the IFNα-2a group had HBsAg negative. The two groups had similar adverse reactions, with no significant difference between the adverse reactions, and no significant adverse events occurred during the two groups. Conclusion PEGINFα-2a is superior to ordinary interferon IFN-2a in the treatment of HBeAg-positive chronic hepatitis B, with good tolerance and safety.